A pivotal trial of Indoximod in combination with PD-1 checkpoint blockade for metastatic melanoma

Trial Profile

A pivotal trial of Indoximod in combination with PD-1 checkpoint blockade for metastatic melanoma

Planning
Phase of Trial: Phase III

Latest Information Update: 28 Jul 2017

At a glance

  • Drugs Indoximod (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Sponsors NewLink Genetics Corporation
  • Most Recent Events

    • 28 Jul 2017 According to a NewLink Genetics Corporation media release, the company anticipates to complete the full enrollment in the trial by the end of 2018.
    • 13 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top